KORU Medical Systems (NASDAQ:KRMD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of KORU Medical Systems (NASDAQ:KRMD) from a buy rating to a strong-buy rating in a research report report published on Monday.

Several other brokerages also recently issued reports on KRMD. Canaccord Genuity Group upped their price target on KORU Medical Systems from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KORU Medical Systems in a research note on Wednesday, October 8th. Finally, Lake Street Capital increased their target price on shares of KORU Medical Systems from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $6.13.

KORU Medical Systems Price Performance

Shares of NASDAQ KRMD opened at $5.57 on Monday. KORU Medical Systems has a fifty-two week low of $1.86 and a fifty-two week high of $6.61. The stock has a market cap of $258.00 million, a price-to-earnings ratio of -69.63 and a beta of 0.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.92 and a current ratio of 2.48. The firm’s 50-day simple moving average is $5.41 and its 200 day simple moving average is $4.42.

Hedge Funds Weigh In On KORU Medical Systems

Institutional investors and hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its holdings in KORU Medical Systems by 189.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company’s stock worth $617,000 after acquiring an additional 158,914 shares during the period. Acuitas Investments LLC purchased a new position in shares of KORU Medical Systems during the 2nd quarter valued at $1,441,000. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of KORU Medical Systems by 23.5% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 82,631 shares of the company’s stock worth $296,000 after buying an additional 15,714 shares in the last quarter. Archon Capital Management LLC raised its position in shares of KORU Medical Systems by 23.5% in the second quarter. Archon Capital Management LLC now owns 700,147 shares of the company’s stock worth $2,507,000 after buying an additional 133,277 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in KORU Medical Systems by 52.1% during the third quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock valued at $39,000 after buying an additional 3,478 shares during the period. 58.60% of the stock is owned by institutional investors.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.